Monte Rosa Therapeutics, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The company is a preclinical biopharmaceutical developer of molecular glue degraders (MGDs), using its QuEEN platform to discover small-molecule protein degraders. It reported no drug-sales revenue and had no approved products. Figures below are in U.S. dollars unless noted.
Financial results and position
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $57.2 million | $24.0 million |
| General and administrative expense | $15.7 million | $4.0 million |
| Total operating expenses | $72.9 million | $28.0 million |
| Net loss | $74.0 million | $35.9 million |
| Net cash used in operating activities | $59.4 million | $23.1 million |
| Net cash used in investing activities | $9.7 million | $3.4 million |
| Cash and cash equivalents at year-end | $346.1 million | $41.7 million |
- At December 31, 2021, cash, cash equivalents and restricted cash totaled $351.4 million, including $5.3 million of restricted cash. The filing does not report a separate balance for marketable investments on the balance sheet.
- Total assets were $366.3 million; total liabilities were $18.8 million. No debt balance is reported. Current assets were $348.7 million and current liabilities $16.6 million.
- There were no product revenues, so gross profit and operating margins are not meaningful. Accumulated deficit was $122.0 million.
- The company raised $377.6 million net cash from financing activities in 2021, principally from preferred-stock financings and its IPO. The IPO raised $255.6 million gross and approximately $234.6 million net, including the underwriters’ option shares.
Material changes versus 2020
- Operating expenses rose $44.9 million, approximately 160%, as the company expanded research activity, staffing and facilities after its IPO. R&D increased $33.2 million; G&A increased $11.7 million.
- Net loss increased $38.1 million, approximately 106%. Operating cash use increased $36.3 million.
- Cash and cash equivalents increased substantially, primarily reflecting the 2021 financings and IPO. All outstanding preferred stock converted to common stock in connection with the IPO.
- R&D staffing increased from 30 to 73 employees; total employees were 93 at year-end.
Business outlook, risks and unusual items
- Pipeline: MRT-2359, an oral GSPT1 degrader for Myc-driven cancers, was the lead program. Management planned to submit an IND in mid-2022 and then begin a Phase 1/2 trial, subject to regulatory clearance. The filing reports only preclinical findings; no candidate had entered clinical trials. CDK2 and NEK7 were in lead optimization; VAV1 and BCL11A and other programs remained in discovery or preclinical development.
- Runway: Management estimated IPO proceeds and existing cash would fund operations into the third quarter of 2024, based on assumptions and without additional collaboration funding. The financial-statement note separately stated cash was expected to cover at least 12 months from issuance of the statements. The company expects continuing losses and will need additional capital to advance programs.
- Development and execution risks: The platform and candidates are unvalidated in humans; clinical safety, efficacy, timing and costs are uncertain. The company depends on third-party manufacturers and service providers and had no long-term supply arrangements. COVID-19 could affect operations, supply, studies or regulatory timing; management said there had been no significant financial or operational impact to date.
- Financial reporting controls: Material weaknesses identified in 2020 remained unremediated at year-end 2021, and management concluded disclosure controls were ineffective. Remediation steps included additional finance staff, consultants, an ERP system and control-design work. The auditor did not audit internal control effectiveness.
- Commitments and other items: Future minimum operating-lease payments were $81.0 million, including the new Boston facility lease. Adoption of lease-accounting standards in 2022 was expected to increase reported assets and liabilities by approximately $6–8 million. The CRT/ICR agreement provides for milestone payments of up to $7.0 million for the first covered product and $3.5 million for each subsequent product, plus low-single-digit royalties on qualifying net sales. A related-party service agreement with Ridgeline was terminated in August 2021; 2021 payments were $7.8 million.
- The company had no material litigation identified by management. Its audited financial statements received an unqualified opinion from Deloitte & Touche LLP.
Key facts for investors to verify
- Whether MRT-2359’s IND was filed and cleared, and whether clinical trials began on the expected timetable; review actual human safety and efficacy data as they become available.
- Cash burn, updated runway assumptions and financing needs relative to the stated Q3 2024 estimate.
- Progress and candidate-selection milestones for CDK2 and NEK7, and evidence supporting the broader platform and other programs.
- Progress in remediating the material weaknesses and any subsequent auditor or management conclusions on internal controls.
- Manufacturing and supplier continuity, lease-related cash commitments, and any milestones or royalties triggered under the CRT/ICR agreements.